Study on bioequivalence of BAY w 6228 between 150μg tablets, and pharmacokinetics following oral administration of BAY w 6228 in dose of 150μg in healthy adult volunteers

Japanese Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 9, 1996, Pages 67-74

  Azuma, Junichi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE;

EID: 0029959479     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hilmar B et al : Pharmacology of the new highly potent HMG-CoA reductase inhibitor cerivastatin (BAY w 6228). Atherosclerosis (in press)
2. Friedewald WT et al : Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 : 499-502, 1972